Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

NCT04484818 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

27

Enrollment

NETWORK

Sponsor class

Conditions

Prostate Carcinoma

Interventions

DRUG: Darolutamide
DRUG: Goserelin Acetate
DRUG: Leuprolide Acetate
DRUG: Placebo Administration
OTHER: Quality-of-Life Assessment
DRUG: Triptorelin

Sponsor

ECOG-ACRIN Cancer Research Group

Collaborators

[object Object]